Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients

REFERENCES

• Odds FC. Candida and Candidosis. A Review and Bibliog-raphy. London: Baillière Tindall; 1988.
   Google Scholar
• Kleinegger CL, Lockhart SR, Vargas K, Soil DR. Fre-quency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol. 1996;34:2246–2254.
   PubMed Web of Science ®Google Scholar
• Johnston RD, Chick EW, Johnston NS, Jarvis MA. Asymp-tomatic quantitative increase of Candida albicans in the oral cavity: Predisposing conditions. South Med J. 1967;60:1244–1247.
   PubMed Web of Science ®Google Scholar
• Stenderup A, Pedusen GT. Yeast of human origin. Acta Pathol Microbiol Scand. 196254: 462–472.
   Google Scholar
• Mackenzie DWR. Yeast from human sources. Sabouraudia. 1962;1:8–15.
   Google Scholar
• van’t Wout JW. Fluconazole treatment of candidal infec-tions caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis. 1996;15:238–242.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Morbiducci V, Ancarani F. Scalise G. Emer-gence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993;9:455–456.
   PubMed Web of Science ®Google Scholar
• Boerlin P, Boerlin-Petzold F, Goudet J, et al. Candida alb/cans oral isolates from human immunodeficiency vi-rus-infected patients by multilocus enzyme electrophore-sis and DNA fingerprinting. J Clin Microbiol. 1996;34:1235–1248.
   PubMed Web of Science ®Google Scholar
• Bette PG. Pathology of some of the opportunistic infec-tions in acquired immune deficiency syndrome (AIDS). Pathologica. 1985;77:67–75.
   PubMedGoogle Scholar
• Chandler FW. Pathology of the mycoses in patients with the acquired immune deficiency syndrome (AIDS). Curr Topics Med Mycol. 1985;1:1–23.
   PubMedGoogle Scholar
• Jaffe HW, Bregman DJ, Selik RM. Acquired immune defi-ciency syndrome in the United States: The first 1,000 cases. J Infect Dis. 1983;148:339–345.
   PubMed Web of Science ®Google Scholar
• Stenderup A, Schonheyder H. Mycoses complicating AIDS. Microbiol Sci. 1984;1:219–223.
   PubMedGoogle Scholar
• Melbye M, Schonheyder H, Kesters L, et al. Carriage of oral Candida albicans associated with a high number of circulating suppressor T lymphocytes [letter]. J Infect Dis. 1985;152:1356–1357.
   PubMed Web of Science ®Google Scholar
• Schonheyder H, Melbye M, Biggar RJ, Ebbesen P, Newland CY, Stenderup A. Oral yeast flora and antibodies to Candida albicans in homosexual men. Mykosen. 1984;27:539–544.
   PubMedGoogle Scholar
• Kalo-Klein A, Witkin SS. Prostaglandin E2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immunity. 1990;58: 260–262.
   PubMed Web of Science ®Google Scholar
• Hippocrates CA, Adams F. Epidemics, Book 3. Baltimore,MD: Williams & Wilkins; 1939.
   Google Scholar
• Coker RJ, Fisher M, Tomlinson DR. Management of my-coses associated with HIV disease. Int J STD AIDS. 1995;6:408–412.
   PubMed Web of Science ®Google Scholar
• Silverman S Jr, Gallo JW, McKnight ML, Mayer P, deSanz S, Tan MM. Clinical characteristics and management re-sponses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radio/ Endod. 1996;82:402–407.
   PubMed Web of Science ®Google Scholar
• Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol. 1994;31:S51–55.
   PubMed Web of Science ®Google Scholar
• Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts. AIDS. 1991;5:519–525.
   PubMed Web of Science ®Google Scholar
• Powderly, WG, Robinson K, Keath EJ. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS. 1992;6:81–84.
   PubMed Web of Science ®Google Scholar
• Darouiche RO. Oropharyngeal and esophageal candidi-asis in immunocompromised patients: Treatment issues. Clin Infect Dis. 1998;26:259–274.
   PubMed Web of Science ®Google Scholar
• Glatt AE, Chirgwin K, Landesman SH. Treatment of infec-tions associated with human immunodeficiency virus. N Engl J Med. 1988;318:1439–1448.
   PubMed Web of Science ®Google Scholar
• Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: Frequencies, associations, and trends. AIDS. 1987;1:175–182.
   PubMed Web of Science ®Google Scholar
• Vazquez J, Lynch M, Boikov D, Sobel JD. Incidence of in vitro antifungal cross resistance among fluconazole-resis-tant Candida albicans and Torulopsis glabrata isolates [abstract]. Proceedings of the 33rd Annual Meeting. Infect Dis Soc Am. 1995;102.
   Google Scholar
• Kozinn PJ, Taschdjian CL, Dragutsky D, et al. Therapy of oral thrush: A comparative evaluation of gentian violet, mycostatin and amphotericin B. Monogr Ther. 1957;2:16–24.
   Google Scholar
• Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: Randomized compari-son of fluconazole versus nystatin oral suspensions. Clin Infect Dis. 1997;24:1204–1207.
   PubMed Web of Science ®Google Scholar
• Quintiliani R, Owens NJ, Quercia RA, Klimek JJ, Nightin-gale CH. Treatment and prevention of oropharyngeal can-didiasis. Am J Med. 1994;77(suppl 4D):44–48.
   Google Scholar
• Yap BS, Bodey GP. Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med. 1979;139:656–657.
   PubMed Web of Science ®Google Scholar
• Shectman LB, Funaro L, Robin T, Bottone EJ, Cuttner J. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med. 1984;76:91–94.
   Web of Science ®Google Scholar
• Pons V, Greenspan D, Debruin M, et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: A ran-domized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J AIDS. 1993;6:1311–1316.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: A controlled study. J Infect Dis. 1983;147:1060–1063.
   PubMed Web of Science ®Google Scholar
• Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Eng J Med. 1994;330:263–272.
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988;1:187–217.
   PubMedGoogle Scholar
• DeWit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal can-didiasis in AIDS. Lancet. 1989;1:746–748.
   PubMed Web of Science ®Google Scholar
• Piscitelli, SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immuno-deficiency virus. Clin Infect Dis. 1996;23:685–693.
   PubMed Web of Science ®Google Scholar
• Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Phar-macokinetic and electrocardiographic consequences. JAMA. 1993;269:1513–1518.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Rodvold KA. Drug biotransformation by the cyto-chrome P-450 enzyme system. Infect Med. 1996;June:452–464.
   Google Scholar
• Murray PA, Koletar SL, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompro-mised patients. Clin Ther. 1997;19:471–480.
   PubMed Web of Science ®Google Scholar
• Hay RJ. Overview of studies of fluconazole in oropharyn-geal candidiasis. Rev Infect Dis. 1990;12\(suppl 3):5334–337.
   Google Scholar
• Meunier F, Aoun M, Gerard M. Therapy of oropharyngeal candidiasis in the immunocompromised host: A random-ized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis. 1990;12\(suppl 3):5364–368.
   Google Scholar
• Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immuno-deficiency virus. Antimicrob Agents Chemother. 1990;34:2267–2268.
   PubMed Web of Science ®Google Scholar
• Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV anti-body-positive group of patients. J Med Vet Mycol. 1988;26:67–71.
   PubMedGoogle Scholar
• Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorp-tion of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46:147–150.
   PubMed Web of Science ®Google Scholar
• Van de Velde VJS, Van Peer AP, Heykants JJP, et al. Effectof food on the pharmacokinetics of a new hydroxypropyl-b-cyclodextrin formulation of itraconazole. Pharmacother. 1996;16:424–428.
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, Hassell AE. En-hanced bioavailability of itraconazole in hydroxypropyl-b-cyclodextrin solution compared with capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42(7)1 862–1865.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Vazquez J, Darouiche RO, et al. Itraconazole oral solution: A novel and effective treatment for oropha-ryngeal candidiasis in HIV/AIDS patients. Am J Med. 1998;104:33–39.
   PubMed Web of Science ®Google Scholar
• Data on file. Janssen Pharmaceutica, Beerse, Belgium.
   Google Scholar
• Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992;36:477–480.
   PubMed Web of Science ®Google Scholar
• Kowalsky SF, Dixon DM. Fluconazole: A new antifungal agent. Clin Pharm. 1991;10:179–194.
   PubMedGoogle Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interactions of azoles with rifampin, phenytoin, and carbamazepine: In vitro and clinical observations. Clin Infect Dis. 1992;14:165–174.
   PubMed Web of Science ®Google Scholar
• Horsburgh CR Jr, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with 21 patients. Am J Med. 1983;74(suppl 1B):23–29.
   PubMedGoogle Scholar
• Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected pa-tients. AIDS. 1994;8:945–950.
   PubMed Web of Science ®Google Scholar
• Quereda C, Polanco AM, Giner C, et al. Correlation be-tween in vitro resistance to fluconazole and clinical out-come of oropharyngeal candidiasis in HIV-infected pa-tients. Eur J Clin Microbiol Infect Dis. 1996;15:30–37.
   PubMed Web of Science ®Google Scholar
• Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-con-trolled trial. Ann Intern Med. 1997;126:689–696.
   PubMed Web of Science ®Google Scholar
• Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Can-dida in patients with AIDS: Prevalence and microbiology. Clin Infect Dis. 1997;24:28–34.
   PubMed Web of Science ®Google Scholar
• Dronda F, Alonso-Sanz M, Laguna F, et al. Mixed oropha-ryngeal candidiasis due to Candida alb/cans and non-alb/cans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996;15:446–452.
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Torssandeer J, Petrini B. Oral Candida alb/ cans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis. 1995;27:391–395.
   PubMed Web of Science ®Google Scholar
• Tavitian A, Raufman J-P, Rosenthal LE, Weber J, Webber CA, Dincsoy HP. Ketoconazole-resistant Candida esoph-agitis in patients with acquired immunodeficiency syn-drome. Gastroenterol. 1986;90:443–445.
   PubMed Web of Science ®Google Scholar
• Barlett JG. 1998 Medical Management of HIV Infection. Baltimore, MD; Port City Press; 1998.
   Google Scholar
• Stevens DA, Greene I, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related com-plex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991151: 2458–2464.
   Google Scholar
• Leen CLS, Dunbar EM, Ellis ME, Mandel BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study. J In-fect. 1990;21:55–60.
   Google Scholar
• Powderly WG, Finkelstein DM, Feinberg J, et al. A ran-domized trial comparing fluconazole with clotrimazole tro-ches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332:700–705.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in pa-tients with advanced HIV infection. Arch Intern Med. 1997;157:64–69.
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996;124:633–642.
   PubMed Web of Science ®Google Scholar
• Dupont B, Denning DW, Marriot D, Sugar A, Viviani MA, Sirisanthana T. Mycosis in AIDS. J Med Vet Mycol. 1994;(supp1)32: 65–77.
   PubMedGoogle Scholar
• Jensen KB, Stenderup A, Thomsen JB. Esophageal monil-iasis in malignant neoplastic disease. Acta Med Scand. 1964;175:455–459.
   PubMed Web of Science ®Google Scholar
• Kodsi BE, Wickremesinghe PC, Kozinn PJ, Iswam K, Goldberg PK. Candida esophagitis: A prospective study of 27 cases. Gastroenterol. 1976;71:715–719.
   PubMed Web of Science ®Google Scholar
• Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut. 1982;23:137–139.
   PubMed Web of Science ®Google Scholar
• Clotet B, Grifol M, Parro B, et al. Asymptomatic esoph-ageal candidiasis in acquired-immunodeficiency-syn-drome-related complex [letter]. Ann Intern Med. 1986;105:145.
   PubMed Web of Science ®Google Scholar
• Ginsburg CH, Braden GL, Tauber Al, Trier JS. Oral clotrimazole in the treatment ofesophageal candidi-asis. Am J Med. 198171: 891–895.
   Google Scholar
• Rutgeerts L, Verhaegen H. Intravenous miconazole in the treatment of chronic esophageal candidiasis. Gastroenterol. 1977;72:316–318.
   PubMed Web of Science ®Google Scholar
• Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis: A prospective study of 12 cases. Am J Gastroesterol. 1983;78:261–264.
   PubMed Web of Science ®Google Scholar
• Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-doseketoconazole.AntimicrobAgents Chemother. 1987;31:1874–1878.
   PubMed Web of Science ®Google Scholar
• De Wit S, Urbain D, Rahir F, Weerts D, Clumeck N. Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. Eur J Clin Microbiol Infect Dis. 1991;10:503–505.
   PubMed Web of Science ®Google Scholar
• Laine L, Dretler RH, Conteas CN, et al. Fluconazole com-pared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med. 1992;117:655–660.
   PubMed Web of Science ®Google Scholar
• Laine L, Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther. 1995;9:553–556.
   PubMed Web of Science ®Google Scholar
• Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind compari-son of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis. 1997;176:227–232.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole com-pared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: A double-blind, random-ized, controlled clinical study. Scand J Infect Dis. 1995;27:613–617.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, DiLorenzo G. Fluconazole versus itraconazole for Can-dida esophagitis in acquired immunodeficiency syn-drome. Gastroenterol. 1996;111:1169–1177.
   PubMed Web of Science ®Google Scholar
• Medoff G, Dismukes WE, Meade RH III, Moses JM. A new therapeutic approach to Candida infections. A pre-liminary report. Arch Intern Med. 1972;130:241–245.
   PubMed Web of Science ®Google Scholar
• Bennett JE. Diagnosis and management of candidiasis inthe immunosuppressed host. Scand J Infect Dis. 1978;(supp1)16: 83–86.
   Google Scholar
• Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemother. 1996;42:308–314.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: A double-blind, placebo controlled study. Endoscopy. 1995;27:377–383.
   PubMed Web of Science ®Google Scholar
• Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: Prevention issues and priorities. Clin Infect Dis. 1995;21\(suppl 1):599–102.
   PubMed Web of Science ®Google Scholar
• Koletar SL, Weed HG, Raimundo MB. Thrush unrespon-sive to treatment with fluconazole in HIV-infected pa-tients. Presented at: First National Conference on Hu-man Retroviruses; January 1994; Washington, DC. Abstract 61.
   Google Scholar
• Vazquez JA, Sobel JD. Epidemiologic overview of resis-tance to oral antifungal agents in the immunocompromised host [abstract]. Excerpta Med/ca. 1997;1–11.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Ant/fungal Suscep-tibility Testing of Yeasts: Approved Standard. Wayne, PA: National Committee for Clinical Laboratory Stan-dards; 1997. NCCLS document M27–A.
   Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility test-ing: Conceptual framework and analysis of in-vitro corre-lation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 1997;24:235–247.
   PubMed Web of Science ®Google Scholar
• Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resis-tance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immu-nodeficiency virus type 1. Antimicrob Agents Chemother. 1993;37:2449–2453.
   PubMed Web of Science ®Google Scholar
• Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immuno-deficiency virus-infected patients. Clin Infect Dis. 1998;26:960–963.
   PubMed Web of Science ®Google Scholar
• Fox R, Neal KR, Leen CLS, Ellis ME, Mandal BK. Fluconazole-resistant Candida in AIDS [letter]. J Infect Dis. 1991;22:201–204.
   Google Scholar
• Kitchen VS, Savage M, Harris JR. Candida alb/cans re-sistance in AIDS [letter]. J Infect Dis. 199122: 204–205.
   Google Scholar
• Horn CA, Washburn RG, Givner LB, Peacock JE Jr, Pegram PS. Azole-resistant oropharyngeal and esoph-ageal candidiasis in patients with AIDS. AIDS. 1995;9:533–534.
   PubMed Web of Science ®Google Scholar
• Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219–225.
   PubMed Web of Science ®Google Scholar
• McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med. 199120: 332–336.
   Google Scholar
• Martins M, Rex JH. Fluconazole suspension for oropha-ryngeal candidiasis unresponsive to tablets [letter]. Ann Intern Med. 1997;126:332–333.
   PubMed Web of Science ®Google Scholar
• Parving H. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med. 1997;126:332–333.
   Web of Science ®Google Scholar
• St.-Germain G, Dion C, Espinel-Ingroff A, RateIle J, de Repentigny L. Ketoconazole and itraconazole suscepti-bility of Candida alb/cans isolated from patients infected with HIV. J Antimicrob Chemother. 1995;36:109–118.
   PubMed Web of Science ®Google Scholar
• Philips P, Zemcov J, Mahmood W, Montaner JSG, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro sus-ceptibility. AIDS. 1996;10:1369–1376.
   PubMed Web of Science ®Google Scholar
• Eichel M, Just-Nübling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal can-didiasis and esophagitis. Mycoses. 1996;39\(suppl 1):102–106.
   PubMed Web of Science ®Google Scholar
• Fessel WJ, Merrill KW, Ward DJ, et al. Itraconazole oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in HIV-positive patients. In: Proceedings of the Fourth Annual Conference on Retroviral Opportunistic Infections; February 1997; Chi-cago. Abstract 124.
   Google Scholar
• Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: The role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS. 1997;11:163–168.
   PubMed Web of Science ®Google Scholar
• Coppola S, Angarano G, Montagna MT, et al. Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei. Eur J Epidemiol. 1995;11:243–244.
   PubMed Web of Science ®Google Scholar
• de Repentigny L, Ratelle J, and the Human Immunodefi-ciency Virus Itraconazole-Ketoconazole Project Group. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal can-didiasis. Chemother. 1996;42:374–383.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Weiss PJ, LaBarre RC, Miller LK, Oldfield EC, Wallace MR. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS. 1996;10:1745–1747.
   Web of Science ®Google Scholar
• Dewsnup, DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol. 1994;32:389–393.
   PubMedGoogle Scholar
• Zingman BS. Treatment of mucosal candidiasis in HIV-infected patients. J Mycol Med. 1996;6:3–11.
   Web of Science ®Google Scholar
• Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B delivery systems. Antimicrob Agents Chemother. 1990;34:381–384.
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immu-nodeficiency virus infection. Antimicrob Agents Chemother. 1997;41:575–577.
   PubMed Web of Science ®Google Scholar
• Law D, Denning DW. In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp. In: Proc 36th Int Conf Antimicrob Agents Chemother; September 1996; New Orleans, LA. Ab-stract 115.
   Google Scholar
• Vazquez J, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 1997;41:1612–1614.
   PubMed Web of Science ®Google Scholar
• Zingman B. Resolution of refractory AIDS-related mu-cosal candidiasis after initiation of didanosine plus saquinavir [letter]. N Engl J Med. 1996;334:1674–1675.
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leuko-cytes from patients with AIDS. J Infect Dis. 1995;171:1448–1454.
   PubMed Web of Science ®Google Scholar
• Bonfati P, Capetti A, De Micheli A, Milella AM, Rizzardini G. HuGM-CSF employment for resistant Candida infec-tions in HIV disease. Presented at: XI International Con-ference on AIDS; July 1996; Vancouver, B.C., Canada. Abstract 286.
   Google Scholar
• Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole-re-sistant oral candidiasis in HIV-infection. Infect Dis Clin Pract. 1997;6:278–279.
   Web of Science ®Google Scholar
• Vazquez JA, Gupta S, Villanueva A. Role of rhu-GM-CSF as adjunctive treatment of antifungal refractory oropha-ryngeal candidiasis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1998;17:781–783.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Vaishampayan J, Arganoza MT, Richards S, Boikov D, Sobel JD. Use of an over the counter product, Breathaway (melaleuca oral solution), as an alternative agent for refractory oropharyngeal candidiasis in AIDS patients. AIDS. 1998;12:1033–1037.
   PubMed Web of Science ®Google Scholar